(MENAFN- GlobeNewsWire - Nasdaq) Oslo, 21 March 2024: Ultimovacs ASA (“Ultimovacs”, ticker ULTI), a clinical-stage biotechnology leader in novel immunotherapeutic cancer vaccines, announces that the Board of Directors of Ultimovacs ASA has approved the Annual Report and ESG Report for 2023.
Please find a PDF version of the annual report, as well as the report in European Single Electronic Format (ESEF), as attachments to this release. The Annual Report is also available at the company's website:
This information is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.
For further information, please see or contact:
Jónas Einarsson, Chairman of the Board of Directors of Ultimovacs ASA
Email: ...
Phone: +47 480 96 355
Carlos de Sousa, CEO
Email: ...
Phone: +47 908 92507
Hans Vassgård Eid, CFO
Email: ...
Phone: +47 482 48632
Anne Worsøe, Head of Investor Relations & ESG
Email: ...
Phone: +47 90686815
Attachments
Ultimovacs-Annual-Report-2023 UltimovacsASA-2023-12-31-en
MENAFN21032024004107003653ID1108003938
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.